ARCT - アルコブラ (Arcturus Therapeutics Ltd.)

ARCTのニュース

   Orbimed Advisors Llc Buys Adagio Therapeutics Inc, Zimmer Biomet Holdings Inc, Biogen Inc, ...  2021/12/24 05:38:01 GuruFocus
Related Stocks: BIIB , IKNA , ABBV , GLPG , SIBN , LUNG , ADGI , ZBH , HCA , ERAS , SGEN , CTKB , PRLD , NTRA , ANTM , AFIB , ABCL , DCPH , AUPH , ASND , TRIL , ARCT , ALXN , ALEC ,
   Arcturus Therapeutics (NASDAQ:ARCT) Shares Gap Up to $42.65  2021/12/23 15:54:45 Dakota Financial News
Arcturus Therapeutics Holdings Inc. (NASDAQ:ARCT)s share price gapped up before the market opened on Thursday . The stock had previously closed at $42.65, but opened at $43.86. Arcturus Therapeutics shares last traded at $42.00, with a volume of 2,855 shares. ARCT has been the subject of a number of analyst reports. Barclays decreased their price []
   Brokerages Expect Arcturus Therapeutics Holdings Inc. (NASDAQ:ARCT) Will Post Quarterly Sales of $12.90 Million  2021/12/22 07:50:44 Transcript Daily
Brokerages predict that Arcturus Therapeutics Holdings Inc. (NASDAQ:ARCT) will report sales of $12.90 million for the current quarter, according to Zacks Investment Research. Four analysts have provided estimates for Arcturus Therapeutics earnings, with the lowest sales estimate coming in at $1.50 million and the highest estimate coming in at $43.40 million. Arcturus Therapeutics reported sales []
   Arcturus Therapeutics (NASDAQ:ARCT) Trading Up 8.9%  2021/12/17 17:40:41 Dakota Financial News
Arcturus Therapeutics Holdings Inc. (NASDAQ:ARCT) was up 8.9% during trading on Friday . The stock traded as high as $46.88 and last traded at $46.83. Approximately 19,475 shares changed hands during trading, a decline of 98% from the average daily volume of 825,301 shares. The stock had previously closed at $43.00. Several research analysts have []
   Brokerages Anticipate Arcturus Therapeutics Holdings Inc. (NASDAQ:ARCT) to Post -$1.81 Earnings Per Share  2021/12/05 15:46:42 Transcript Daily
Equities research analysts expect Arcturus Therapeutics Holdings Inc. (NASDAQ:ARCT) to report ($1.81) earnings per share (EPS) for the current quarter, Zacks Investment Research reports. Four analysts have made estimates for Arcturus Therapeutics earnings, with estimates ranging from ($2.31) to ($0.80). Arcturus Therapeutics posted earnings of ($1.25) per share in the same quarter last year, which []
   Arcturus Therapeutics Holdings Inc. (NASDAQ:ARCT) Expected to Announce Earnings of -$1.81 Per Share  2021/11/30 16:20:42 Dakota Financial News
Brokerages expect that Arcturus Therapeutics Holdings Inc. (NASDAQ:ARCT) will announce earnings per share (EPS) of ($1.81) for the current quarter, according to Zacks. Four analysts have made estimates for Arcturus Therapeutics earnings, with estimates ranging from ($2.31) to ($0.80). Arcturus Therapeutics reported earnings of ($1.25) per share in the same quarter last year, which indicates []
   Charles Schwab Investment Management Inc. Boosts Stock Holdings in Arcturus Therapeutics Holdings Inc. (NASDAQ:ARCT)  2021/11/22 09:42:42 Transcript Daily
Charles Schwab Investment Management Inc. lifted its stake in shares of Arcturus Therapeutics Holdings Inc. (NASDAQ:ARCT) by 4.4% during the second quarter, Holdings Channel reports. The fund owned 144,621 shares of the biotechnology companys stock after acquiring an additional 6,095 shares during the period. Charles Schwab Investment Management Inc.s holdings in Arcturus Therapeutics were worth []
   Arcturus Therapeutics (NASDAQ:ARCT) Rating Lowered to Sell at Zacks Investment Research  2021/11/15 08:48:42 Transcript Daily
Zacks Investment Research downgraded shares of Arcturus Therapeutics (NASDAQ:ARCT) from a hold rating to a sell rating in a research note issued to investors on Thursday, Zacks.com reports. According to Zacks, Arcturus Therapeutics Ltd. is a preclinical-stage biopharmaceutical company. It focuses on the discovery, development and commercialization of RNA medicines using proprietary lipid-mediated delivery system []
   $10.46 Million in Sales Expected for Arcturus Therapeutics Holdings Inc. (NASDAQ:ARCT) This Quarter  2021/11/13 09:24:41 Dakota Financial News
Wall Street analysts expect Arcturus Therapeutics Holdings Inc. (NASDAQ:ARCT) to post sales of $10.46 million for the current fiscal quarter, according to Zacks. Five analysts have issued estimates for Arcturus Therapeutics earnings, with the lowest sales estimate coming in at $700,000.00 and the highest estimate coming in at $43.40 million. Arcturus Therapeutics posted sales of []
   Arcturus Therapeutics Holdings Inc. Forecasted to Post FY2021 Earnings of ($8.38) Per Share (NASDAQ:ARCT)  2021/11/13 08:34:41 Transcript Daily
Arcturus Therapeutics Holdings Inc. (NASDAQ:ARCT) Equities research analysts at Cantor Fitzgerald decreased their FY2021 earnings estimates for shares of Arcturus Therapeutics in a research note issued on Tuesday, November 9th. Cantor Fitzgerald analyst B. Cheng now expects that the biotechnology company will earn ($8.38) per share for the year, down from their prior estimate []
   Cantor Fitzgerald Stick to Their Buy Rating for Arcturus Therapeutics By Investing.com  2021/11/05 09:12:33 Investing.com
Cantor Fitzgerald Stick to Their Buy Rating for Arcturus Therapeutics
   Analysts Anticipate Arcturus Therapeutics Holdings Inc. (NASDAQ:ARCT) Will Announce Quarterly Sales of $26.70 Million  2021/10/30 20:58:41 Dakota Financial News
Wall Street analysts predict that Arcturus Therapeutics Holdings Inc. (NASDAQ:ARCT) will post sales of $26.70 million for the current fiscal quarter, according to Zacks. Five analysts have issued estimates for Arcturus Therapeutics earnings, with the lowest sales estimate coming in at $1.80 million and the highest estimate coming in at $73.02 million. Arcturus Therapeutics posted []
   -$1.40 Earnings Per Share Expected for Arcturus Therapeutics Holdings Inc. (NASDAQ:ARCT) This Quarter  2021/10/30 20:58:41 Transcript Daily
Brokerages expect that Arcturus Therapeutics Holdings Inc. (NASDAQ:ARCT) will post ($1.40) earnings per share for the current quarter, according to Zacks Investment Research. Five analysts have provided estimates for Arcturus Therapeutics earnings, with the lowest EPS estimate coming in at ($2.59) and the highest estimate coming in at $0.30. Arcturus Therapeutics reported earnings of ($0.92) []
   Arcturus Therapeutics to Report Third Quarter 2021 Financial Results and Provide Corporate Update on November 8, 2021  2021/10/25 20:00:00 Business Wire
SAN DIEGO--(BUSINESS WIRE)---- $ARCT #ClinicalTrial--Arcturus Therapeutics Holdings Inc. (the “Company”, “Arcturus”, Nasdaq: ARCT), a leading clinical-stage messenger RNA medicines company focused on the development of infectious disease vaccines and significant opportunities within liver and respiratory rare diseases, today announced that it will release its financial results for the third quarter ended September 30, 2021 after the market close on Monday November 8, and will also host a conference call and webcast at
   Arcturus Therapeutics Holdings Inc. (NASDAQ:ARCT) Expected to Post Quarterly Sales of $26.70 Million  2021/10/25 06:32:40 Transcript Daily
Equities analysts forecast that Arcturus Therapeutics Holdings Inc. (NASDAQ:ARCT) will announce $26.70 million in sales for the current quarter, Zacks Investment Research reports. Five analysts have made estimates for Arcturus Therapeutics earnings. The highest sales estimate is $73.02 million and the lowest is $1.80 million. Arcturus Therapeutics posted sales of $2.33 million during the same []

calendar